We will push forward with research and development to obtain manufacturing and marketing approval for human iPS cell-derived cardiomyocyte patch. We expect these patches will improve heart functions with severe heart failure patients for whom there is no effective options other heart transplantation and artificial heart implantation.

In October 2019, the research group of Osaka University, our exclusive research partner, launched an investigator-initiated clinical trial. The group transplanted our human iPS cell-derived cardiomyocyte patch in the first patient in January 2020 and completed for three patients by December 2020.

We will continue our efforts in investigator-initiated clinical trials and delivering our products to severe heart failure patients.

Cuorips helps people live healthy andinproves QOL.